One of them is miR-34a, which was demonstrated to increase resistance to docetaxel (DTX) in luminal BC cells, probably through the inhibition of cyclin D1 (CCND1) and B-cell lymphoma 2 (Bcl-2), inducing G1 arrest and blocking DTX effectiveness as a consequence [139]. Here, BCL2 is linked to breast cancer.